Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: A systematic review and meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 11, 2009, Pages 1483-1493

  Carlson, Josh John ^a   Garrison, Louis P ^a   Ramsey, Scott D ^a,b   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

EGFR; Erlotinib; Gefitinib; Non small cell; Response; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE MARKER; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOMICS; HEALTH CARE QUALITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; DRUG ANTAGONISM; GENE DOSAGE; GENETICS; LUNG TUMOR; MUTATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; STATISTICAL ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; DATA INTERPRETATION, STATISTICAL; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70349563747     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0595-3     Document Type: Article

References (56)

1. American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta
2. A Argiris T Hensing A Yeldandi S Patel A Raji C Sturgis, et al. 2006 Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story J Thorac Oncol 1 1 52 60 10.1097/01243894-200601000- 00011 17409827 10.1097/01243894-200601000-00011
3. DW Bell TJ Lynch SM Haserlat PL Harris RA Okimoto BW Brannigan, et al. 2005 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 31 8081 8092 10.1200/JCO.2005.02.7078 16204011 10.1200/JCO.2005.02.7078 (Pubitemid 46657411)
4. PA Bunn Jr R Dziadziuszko M Varella-Garcia WA Franklin SE Witta K Kelly, et al. 2006 Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy Clin Cancer Res 12 12 3652 3656 10.1158/1078-0432.CCR-06-0261 16778092 10.1158/1078-0432.CCR-06-0261 (Pubitemid 44000246)
5. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis, et al. 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 9 643 655 15870435 (Pubitemid 40812628)
6. F Cappuzzo C Ligorio PA Janne L Toschi E Rossi R Trisolini, et al. 2007 Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial J Clin Oncol 25 16 2248 2255 10.1200/JCO.2006.09.4300 17538169 10.1200/JCO.2006.09.4300 (Pubitemid 46954651)
7. TY Chou CH Chiu LH Li CY Hsiao CY Tzen KT Chang, et al. 2005 Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 11 10 3750 3757 10.1158/1078-0432.CCR-04-1981 15897572 10.1158/1078-0432.CCR-04-1981 (Pubitemid 40685592)
8. H Cortes-Funes C Gomez R Rosell P Valero C Garcia-Giron A Velasco, et al. 2005 Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 16 7 1081 1086 10.1093/annonc/mdi221 15851406 10.1093/annonc/mdi221 (Pubitemid 41418309)
9. DA Eberhard BE Johnson LC Amler AD Goddard SL Heldens RS Herbst, et al. 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 25 5900 5909 10.1200/JCO.2005.02.857 16043828 10.1200/JCO.2005.02.857 (Pubitemid 46300206)
10. DA Eberhard G Giaccone BE Johnson 2008 Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting J Clin Oncol 26 6 983 994 10.1200/JCO.2007.12.9858 18281673 10.1200/JCO.2007.12.9858
11. G Giaccone M Gallegos Ruiz T Le Chevalier N Thatcher E Smit JA Rodriguez, et al. 2006 Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study Clin Cancer Res 12 20 Pt 1 6049 6055 10.1158/1078-0432.CCR-06-0260 17062680 10.1158/1078-0432.CCR-06-0260 (Pubitemid 44703768)
12. S Greenland 1987 Quantitative methods in the review of epidemiologic literature Epidemiol Rev 9 1 30 3678409
13. DA Haas-Kogan MD Prados KR Lamborn T Tihan MS Berger D Stokoe 2005 Biomarkers to predict response to epidermal growth factor receptor inhibitors Cell Cycle 4 10 1369 1372 16177570 (Pubitemid 41437124)
14. SW Han PG Hwang DH Chung DW Kim SA Im YT Kim, et al. 2005 Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer Int J Cancer 113 1 109 115 10.1002/ijc.20550 15386420 10.1002/ijc.20550 (Pubitemid 39507317)
15. SW Han TY Kim YK Jeon PG Hwang SA Im KH Lee, et al. 2006 Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Clin Cancer Res 12 8 2538 2544 10.1158/1078-0432.CCR-05-2845 16638863 10.1158/1078-0432.CCR-05-2845
16. SW Han TY Kim KH Lee PG Hwang YK Jeon DY Oh, et al. 2006 Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients Lung Cancer 54 2 201 207 10.1016/j.lungcan.2006.07.007 16956694 10.1016/j.lungcan.2006.07.007 (Pubitemid 44764917)
17. FR Hirsch S Witta 2005 Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer Curr Opin Oncol 17 2 118 122 10.1097/01.cco.0000155059.39733.9d 15725915 10.1097/01.cco.0000155059.39733.9d (Pubitemid 40516280)
18. FR Hirsch M Varella-Garcia PA Bunn Jr WA Franklin R Dziadziuszko N Thatcher, et al. 2006 Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 31 5034 5042 10.1200/JCO.2006.06.3958 17075123 10.1200/JCO.2006.06.3958 (Pubitemid 46631407)
19. FR Hirsch M Varella-Garcia F Cappuzzo J McCoy L Bemis AC Xavier, et al. 2007 Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib Ann Oncol 18 4 752 760 10.1093/annonc/mdm003 17317677 10.1093/annonc/mdm003 (Pubitemid 46523281)
20. MH Hsieh YF Fang WC Chang HP Kuo SY Lin HP Liu, et al. 2006 Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer Lung Cancer 53 3 311 322 10.1016/j.lungcan.2006.06.005 16870303 10.1016/j.lungcan.2006.06.005 (Pubitemid 44189569)
21. S Ichihara S Toyooka Y Fujiwara K Hotta H Shigematsu M Tokumo, et al. 2007 The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer Int J Cancer 120 6 1239 1247 10.1002/ijc.22513 17192902 10.1002/ijc.22513 (Pubitemid 46256776)
22. DM Jackman BY Yeap NI Lindeman P Fidias MS Rabin J Temel, et al. 2007 Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 25 7 760 766 10.1200/JCO.2006.07.5754 17228019 10.1200/JCO.2006.07.5754 (Pubitemid 350002874)
23. BE Johnson PA Janne 2005 Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations? J Clin Oncol 23 28 6813 6816 10.1200/JCO.2005.97.008 16145056 10.1200/JCO.2005.97.008 (Pubitemid 46260266)
24. Kelley MJ, McCrory D (2005) Report on the relative efficacy of oral cancer therapy for medicare beneficiaries versus currently covered therapy: part 1, gefitinib and erlotinib for non-small cell lung cancer. Agency for Healthcare Research and Quality, Rockville
25. KS Kim JY Jeong YC Kim KJ Na YH Kim SJ Ahn, et al. 2005 Predictors of the response to gefitinib in refractory non-small cell lung cancer Clin Cancer Res 11 6 2244 2251 10.1158/1078-0432.CCR-04-2081 15788673 10.1158/1078-0432.CCR-04- 2081 (Pubitemid 40490183)
26. M Kondo T Yokoyama T Fukui H Yoshioka K Yokoi T Nagasaka, et al. 2005 Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery Lung Cancer 50 3 385 391 10.1016/j.lungcan.2005.06.008 16140420 10.1016/j.lungcan. 2005.06.008 (Pubitemid 43300638)
27. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 2129 2139 10.1056/NEJMoa040938 15118073 10.1056/NEJMoa040938 (Pubitemid 38637993)
28. T Mitsudomi T Kosaka H Endoh 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence J Clin Oncol 23 11 2513 2520 10.1200/JCO.2005.00.992 15738541 10.1200/JCO.2005.00.992 (Pubitemid 47050841)
29. XL Mu LY Li XT Zhang MZ Wang RE Feng QC Cui, et al. 2005 Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer Clin Cancer Res 11 12 4289 4294 10.1158/1078-0432.CCR-04-2506 15958609 10.1158/1078-0432. CCR-04-2506 (Pubitemid 40825615)
30. NCCN (2006) NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.2.2006. NCCN, Fort Washington
31. NICE (2006) ERG report: erlotinib for the treatment of relapsed non-small cell lung cancer. The National Institute for Health and Clinical Excellence, Liverpool
32. S Niho K Kubota K Goto K Yoh H Ohmatsu R Kakinuma, et al. 2006 First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study J Clin Oncol 24 1 64 69 10.1200/JCO.2005.02.5825 16382114 10.1200/JCO.2005.02.5825 (Pubitemid 46630495)
33. F Oshita S Matsukuma M Yoshihara Y Sakuma N Ohgane Y Kameda, et al. 2006 Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer Br J Cancer 95 8 1070 1075 10.1038/sj.bjc.6603396 17047654 10.1038/sj.bjc.6603396 (Pubitemid 44606834)
34. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 1497 1500 10.1126/science.1099314 15118125 10.1126/science.1099314 (Pubitemid 38720929)
35. W Pao V Miller M Zakowski J Doherty K Politi I Sarkaria, et al. 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 36 13306 13311 10.1073/pnas.0405220101 15329413 10.1073/pnas.0405220101 (Pubitemid 39209661)
36. HS Parra R Cavina F Latteri PA Zucali E Campagnoli E Morenghi, et al. 2004 Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer Br J Cancer 91 2 208 212 15187994 (Pubitemid 39037060)
37. Pettiti D (2000) Meta-analysis, decision Analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, New York
38. GJ Riely W Pao D Pham AR Li N Rizvi ES Venkatraman, et al. 2006 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 12 3 Pt 1 839 844 10.1158/1078-0432.CCR-05-1846 16467097 10.1158/1078-0432.CCR-05-1846 (Pubitemid 43259866)
39. R Rosell Y Ichinose M Taron C Sarries C Queralt P Mendez, et al. 2005 Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer Lung Cancer 50 1 25 33 10.1016/j.lungcan.2005.05.017 16011858 10.1016/j.lungcan.2005.05.017 (Pubitemid 41297466)
40. M Satouchi S Negoro Y Funada Y Urata T Shimada S Yoshimura, et al. 2007 Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib Br J Cancer 96 8 1191 1196 10.1038/sj.bjc.6603710 17387341 10.1038/sj.bjc.6603710 (Pubitemid 46625078)
41. LV Sequist VA Joshi PA Janne A Muzikansky P Fidias M Meyerson, et al. 2007 Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing Oncologist 12 1 90 98 10.1634/theoncologist.12-1-90 17285735 10.1634/theoncologist.12-1-90 (Pubitemid 46143506)
42. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 123 132 10.1056/NEJMoa050753 16014882 10.1056/NEJMoa050753 (Pubitemid 41058344)
43. H Shigematsu L Lin T Takahashi M Nomura M Suzuki II Wistuba, et al. 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 5 339 346 15741570 (Pubitemid 40425952)
44. JY Shih CH Gow CJ Yu CH Yang YL Chang MF Tsai, et al. 2006 Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer Int J Cancer 118 4 963 969 10.1002/ijc.21458 16152581 10.1002/ijc.21458 (Pubitemid 43157672)
45. T Sone K Kasahara H Kimura K Nishio M Mizuguchi Y Nakatsumi, et al. 2007 Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer Cancer 109 9 1836 1844 10.1002/cncr.22593 17387741 10.1002/cncr.22593 (Pubitemid 46668548)
46. T Takano Y Ohe H Sakamoto K Tsuta Y Matsuno U Tateishi, et al. 2005 Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 23 28 6829 6837 10.1200/JCO.2005.01.0793 15998907 10.1200/JCO.2005.01.0793 (Pubitemid 46260269)
47. M Taron Y Ichinose R Rosell T Mok B Massuti L Zamora, et al. 2005 Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 16 5878 5885 10.1158/1078-0432.CCR-04-2618 16115929 10.1158/1078-0432.CCR-04-2618 (Pubitemid 41170316)
48. M Tokumo S Toyooka K Kiura H Shigematsu K Tomii M Aoe, et al. 2005 The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 3 1167 1173 15709185 (Pubitemid 40175767)
49. Y Tomizawa H Iijima N Sunaga K Sato A Takise Y Otani, et al. 2005 Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer Clin Cancer Res 11 19 Pt 1 6816 6822 10.1158/1078-0432.CCR-05-0441 16203769 10.1158/1078-0432.CCR-05- 0441 (Pubitemid 41428736)
50. MS Tsao A Sakurada JC Cutz CQ Zhu S Kamel-Reid J Squire, et al. 2005 Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 2 133 144 10.1056/NEJMoa050736 16014883 10.1056/NEJMoa050736 (Pubitemid 41058345)
51. H Uramoto T Mitsudomi 2007 Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96 6 857 863 10.1038/sj.bjc.6603665 17325698 10.1038/sj.bjc.6603665 (Pubitemid 46452294)
52. H Uramoto K Sugio T Oyama K Ono M Sugaya T Yoshimatsu, et al. 2006 Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese Lung Cancer 51 1 71 77 10.1016/j.lungcan.2005.08.006 16198442 10.1016/j.lungcan.2005.08.006 (Pubitemid 43088626)
53. M Varella-Garcia 2006 Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay Diagn Pathol 1 19 10.1186/1746-1596-1- 19 16911776 10.1186/1746-1596-1-19
54. YL Wu WZ Zhong LY Li XT Zhang L Zhang CC Zhou, et al. 2007 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China J Thorac Oncol 2 5 430 439 10.1097/01.JTO.0000268677.87496.4c 17473659 10.1097/01.JTO.0000268677.87496.4c (Pubitemid 47181698)
55. CH Yang JY Shih KC Chen CJ Yu TY Yang CP Lin, et al. 2006 Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer Cancer 107 8 1873 1882 10.1002/cncr.22220 16989002 10.1002/cncr.22220 (Pubitemid 44582958)
56. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2 127 137 10.1038/35052073 11252954 10.1038/35052073 (Pubitemid 33674041)